At Empa, we develop cutting-edge treatments for a wide range of eye diseases. Our work includes treatments for corneal ulcers, painful infections on the surface of the eye that affect around 6 million people annually. We are also pioneering innovative approaches to managing glaucoma, which currently affects over 76 million people worldwide and is a leading cause of irreversible blindness. Additionally, we are addressing cataracts, the leading cause of blindness globally, which accounts for 51% of all blindness cases, through improved surgical techniques and treatment methods.
Moreover, we are exploring alternative methods for sutures to improve surgical outcomes, reduce recovery times, and enhance the healing process after eye surgeries or injuries. In parallel, our research also focuses on developing better treatments against bacterial infections of the eye, which can lead to severe complications if left untreated.

Since eye diseases are so widespread in the current society, our mission is not only to develop new treatments, but also to ensure that these innovations are accessible and effective for the millions of people worldwide suffering from sight impairments.